Evidence map›Paper›PMID 38920845›Full record

ReviewInternational journal of neonatal screening2024

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Bradford L Therrell, Carmencita D Padilla, Gustavo J C Borrajo, Issam Khneisser, Peter C J I Schielen, Jennifer Knight-Madden, Helen L Malherbe, Marika Kase

Abstract readReview
In one paragraph

Review in International journal of neonatal screening, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Universal newborn screening for G6PD deficiency and severe hyperbilirubinemia at a tertiary center in Jerusalem.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Propionic acidemia in Mexico: Clinical and genotypic spectrum.Molecular genetics and metabolism reports · 2026
    Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bradford L TherrellDepartment of Pediatrics, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0001-6272-7350
Carmencita D PadillaDepartment of Pediatrics, College of Medicine, University of the Philippines Manila, Manila 1000, Philippines.ORCID 0000-0002-5812-1871
Gustavo J C BorrajoDetección de Errores Congénitos-Fundación Bioquímica Argentina, La Plata 1908, Argentina.ORCID 0000-0001-6129-4987
Issam KhneisserJacques LOISELET Genetic and Genomic Medical Center, Faculty of Medicine, Saint Joseph University, Beirut 1104 2020, Lebanon.ORCID 0000-0003-4067-1063
Peter C J I SchielenOffice of the International Society for Neonatal Screening, Reigerskamp 273, 3607 HP Maarssen, The Netherlands.ORCID 0000-0002-5630-7322
Jennifer Knight-MaddenCaribbean Institute for Health Research-Sickle Cell Unit, The University of the West Indies, Mona, Kingston 7, Jamaica.
Helen L MalherbeCentre for Human Metabolomics, North-West University, Potchefstroom 2531, South Africa.ORCID 0000-0002-9566-6248
Marika KaseStrategic Initiatives Reproductive Health, Revvity, PL10, 10101 Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert "Bob" Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transported to a remote testing laboratory began it all. Expansion of NBS to large numbers of asymptomatic congenital conditions flourishes in many settings while it has not yet been realized in others. The need for NBS as an efficient and effective public health prevention strategy that contributes to lowered morbidity and mortality wherever it is sustained is well known in the medical field but not necessarily by political policy makers. Acknowledging the value of national NBS reports published in 2007, the authors collaborated to create a worldwide NBS update in 2015. In a continuing attempt to review the progress of NBS globally, and to move towards a more harmonized and equitable screening system, we have updated our 2015 report with information available at the beginning of 2024. Reports on sub-Saharan Africa and the Caribbean, missing in 2015, have been included. Tables popular in the previous report have been updated with an eye towards harmonized comparisons. To emphasize areas needing attention globally, we have used regional tables containing similar listings of conditions screened, numbers of screening laboratories, and time at which specimen collection is recommended. Discussions are limited to bloodspot screening.

Indexed as

Asia–PacificCaribbeanEuropeglobalinternational dataLatin AmericaMiddle East North Africanewborn screeningNorth AmericaSub-Saharan Africa

Identifiers

PMID38920845
PMCPMC11203842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.